JBS N.V. Class A JBS 深 沪
等待开盘 08-20 09:30:00 美东时间
13.75
+0.090
+0.66%
华盛通- 最 高14.315
- 今 开13.86
- 成交量 725.83万股
- 最 低 13.68
- 昨 收 13.66
- 总市值 452.29亿
- 52周最高 17.65
- 市盈率 静 7.25
- 换手率 0.22%
- 52周最低 11.37
- 委 比 -27.39%
- 总股本 32.89亿
- 历史最高 17.65
- 量 比 1.21
- 振 幅 4.65%
- 历史最低 11.37
- 每 手 1
- 风险率 1.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
JP Morgan Maintains Overweight on JBS, Lowers Price Target to $17.5
JP Morgan analyst Lucas Ferreira maintains JBS (NYSE:JBS) with a Overweight and lowers the price target from $18 to $17.5.
08-12 22:37
财报速睇 | JBS N.V. Class A 2026财年Q2营收239.00亿美元，同比增长13.8%；归母净利润亏损1.02亿美元，由盈转亏
华盛资讯8月11日讯，JBS N.V. Class A公布2026财年Q2业绩，公司Q2营收239.00亿美元，同比增长13.8%，归母净利润亏损1.02亿美元，由盈转亏。
08-11 18:39
财报速睇 | JBS N.V. Class A 2026财年Q2营收239.00亿美元，同比增长13.8%；归母净利润亏损1.02亿美元，由盈转亏
华盛资讯8月11日讯，JBS N.V. Class A公布2026财年Q2业绩，公司Q2营收239.00亿美元，同比增长13.8%，归母净利润亏损1.02亿美元，由盈转亏。
08-11 05:35
JBS Q2 EPS $(0.09) Misses $0.32 Estimate, Sales $23.899B Beat $22.903B Estimate
JBS (NYSE:JBS) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $0.32 by 128.13 percent. This is a 118.75 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $23.899 billion which beat ...
08-11 05:24
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
JP Morgan Upgrades JBS to Overweight, Maintains Price Target to $18
JP Morgan analyst Lucas Ferreira upgrades JBS (NYSE:JBS) from Neutral to Overweight and maintains the price target from $18 to $18.
07-28 18:45
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Monday. Shares of Baker Hughes Co (NASDAQ:BKR) rose sharply after the company reported better-than-expected second-quarter financial results. Also, it received a technology order from Venture Global for its CP2 LNG projec...
07-27 22:35
